Live Earnings Conference Call: BioMarin Pharmaceutical will host a live Q1 2025 earnings call on May 1, 2025 at 4:30PM ET. Follow this link to get details and listen to BioMarin Pharmaceutical's Q1 2025 earnings call when it goes live. Get details. BioMarin Pharmaceutical (BMRN) Competitors $63.15 -0.54 (-0.85%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BMRN vs. ALNY, BIIB, UTHR, INCY, NBIX, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. BioMarin Pharmaceutical vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends. Is BMRN or ALNY more profitable? BioMarin Pharmaceutical has a net margin of 14.96% compared to Alnylam Pharmaceuticals' net margin of -12.37%. BioMarin Pharmaceutical's return on equity of 9.91% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioMarin Pharmaceutical14.96% 9.91% 7.65% Alnylam Pharmaceuticals -12.37%N/A -6.83% Which has preferable earnings & valuation, BMRN or ALNY? BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioMarin Pharmaceutical$2.85B4.26$167.65M$2.2028.95Alnylam Pharmaceuticals$2.25B15.23-$278.16M-$2.17-121.31 Which has more volatility and risk, BMRN or ALNY? BioMarin Pharmaceutical has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Does the MarketBeat Community prefer BMRN or ALNY? BioMarin Pharmaceutical received 417 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.28% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.61% of users gave BioMarin Pharmaceutical an outperform vote. CompanyUnderperformOutperformBioMarin PharmaceuticalOutperform Votes158174.61% Underperform Votes53825.39% Alnylam PharmaceuticalsOutperform Votes116476.28% Underperform Votes36223.72% Do analysts rate BMRN or ALNY? BioMarin Pharmaceutical currently has a consensus target price of $93.14, indicating a potential upside of 46.24%. Alnylam Pharmaceuticals has a consensus target price of $315.58, indicating a potential upside of 19.88%. Given BioMarin Pharmaceutical's higher possible upside, equities research analysts clearly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioMarin Pharmaceutical 0 Sell rating(s) 7 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.70Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Does the media refer more to BMRN or ALNY? In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 24 mentions for Alnylam Pharmaceuticals and 17 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 1.35 beat Alnylam Pharmaceuticals' score of 1.02 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 15 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 17 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of BMRN or ALNY? 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryBioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.15B$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio28.957.4422.4418.48Price / Sales4.26242.70393.95103.59Price / Cash21.1765.8538.1834.62Price / Book2.156.516.774.25Net Income$167.65M$143.21M$3.22B$248.23M7 Day Performance1.51%1.98%1.45%0.89%1 Month Performance-6.26%6.89%3.96%3.53%1 Year Performance-23.57%-2.52%16.07%5.08% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.9305 of 5 stars$63.15-0.9%$93.14+47.5%-21.1%$12.06B$2.85B28.733,080Positive NewsALNYAlnylam Pharmaceuticals4.222 of 5 stars$232.75-0.8%$315.58+35.6%+82.9%$30.28B$2.25B-107.262,000Earnings ReportAnalyst DowngradePositive NewsBIIBBiogen4.6945 of 5 stars$116.49-1.8%$213.15+83.0%-43.6%$17.05B$9.68B10.418,720Earnings ReportAnalyst DowngradeAnalyst RevisionNews CoverageUTHRUnited Therapeutics4.9809 of 5 stars$284.25-0.2%$395.67+39.2%+29.3%$12.77B$2.88B12.48980Earnings ReportAnalyst RevisionNews CoveragePositive NewsINCYIncyte4.7149 of 5 stars$56.80-2.4%$74.69+31.5%+20.4%$10.99B$4.24B210.382,320Earnings ReportAnalyst ForecastNBIXNeurocrine Biosciences4.8738 of 5 stars$100.68-0.7%$161.86+60.8%-21.7%$9.96B$2.36B30.601,200Upcoming EarningsAnalyst ForecastAnalyst RevisionEXELExelixis4.0819 of 5 stars$35.59-1.7%$37.59+5.6%+66.9%$9.96B$2.17B20.111,220Short Interest ↑Analyst RevisionPositive NewsEXASExact Sciences4.4898 of 5 stars$43.10+3.7%$69.25+60.7%-23.1%$8.01B$2.76B-7.746,400RGENRepligen4.8597 of 5 stars$131.64+1.3%$176.82+34.3%-16.0%$7.39B$634.44M-258.122,020Earnings ReportAnalyst UpgradeAnalyst RevisionNews CoverageHALOHalozyme Therapeutics4.0007 of 5 stars$57.29-2.6%$62.89+9.8%+61.2%$7.08B$1.02B16.70390Upcoming EarningsInsider TradeAnalyst RevisionNews CoverageMDGLMadrigal Pharmaceuticals3.7511 of 5 stars$295.02-2.2%$378.44+28.3%+63.7%$6.51B$180.13M-11.7690Earnings ReportNews CoveragePositive NewsGap Up Related Companies and Tools Related Companies ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors EXEL Competitors EXAS Competitors RGEN Competitors HALO Competitors MDGL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BMRN Stock Free BMRN Stock Alerts